ClinicalTrials.gg
CompletedNCT05166889OBERONUpdated Apr 16, 2026

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase 3 interventional study of Tozorakimab and Tozorakimab in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 212 sites in 21 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,132
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
29th of 194
1,132 · median 137
Started
2022
with 9 others
Phase 3
76 of 284
4 open now
Registered
236th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 29th largest by enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2022, is one of 76 in phase 3, and was the 236th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • tozorakimab
  • exacerbations
  • ICS
  • LABA/LAMA
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 40 years of age and capable of giving signed .
  2. Documented diagnosis of for at least one year prior to enrolment.
  3. Post BD /FVC \< 0.70 and post-BD FEV1 >20% of predicted normal value.
  4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
  6. Smoking history of ≥ 10 pack-years.
  7. CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2.

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than .
  2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.
  3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
  4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
  5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic and/or antibiotics, and/or led to hospitalization.
  6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
  7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
  8. Significant COVID-19 illness within the 6 months prior to enrolment.
  9. Unstable cardiovascular disorder.
  10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
  11. History of known immunodeficiency disorder, including a positive test for -1 or HIV 2.
  12. History of positive test or treatment for or (except for cured hepatitis C)
  13. Evidence of active liver disease, including jaundice during screening.
  14. , current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
  15. Participants who have evidence of active TB.
  16. Participants that have previously received tozorakimab.
  17. Any clinically significant abnormal findings in physical examination, vital signs, , or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
  18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,132 participants (actual)

Study arms

  • Experimental
    Tozorakimab Dose 1

    Dosing subcutaneously tozorakimab Dose 1 and placebo

    Drug: Tozorakimab

  • Experimental
    Tozorakimab Dose 2

    Dosing subcutaneously tozorakimab Dose 2

    Drug: Tozorakimab

  • Placebo comparator
    Placebo

    Dosing subcutaneously with equivalent volume to tozorakimab

    Drug: Placebo

Interventions

  • Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

  • Administered subcutaneously tozorakimab Dose 2 through Week 52.

  • DrugPlacebo

    Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.

06

What researchers measure

Primary outcomes

  1. Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.

    The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy \[triple therapy, or dual therapy if triple is not considered appropriate\]) and then assessed in the overall population of participants.

    Time frame: over 52 weeks

Secondary outcomes

  1. Annualized rate of moderate to severe COPD exacerbations in former or current smokers.

    The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.

    Time frame: over 52 weeks

  2. Time to first moderate to severe COPD exacerbation in former smokers.

    To explore the extent to which treatment with each dose of tozorakimab delays the time to first exacerbation compared with placebo in former smokers.

    Time frame: over 52 weeks

  3. Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.

    Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.

    Time frame: Week 52, or over 52 weeks

  4. Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in the overall population of current and former smokers.

    Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.

    Time frame: Week 52, or over 52 weeks

  5. Percentage of responders achieving MCID in E-RS:COPD total score in former smokers.

    Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in former smokers.

    Time frame: Week 52

  6. Percentage of responders achieving MCID in E-RS:COPD total score in the overall population of current and former smokers.

    Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in the overall population of current and former smokers.

    Time frame: Week 52

  7. Mean change from baseline in E-RS:COPD total score in former smokers.

    Difference in mean change in E-RS:COPD total score from baseline in former smokers.

    Time frame: over 52 weeks

  8. Mean change from baseline in E-RS:COPD total score in the overall population of current and former smokers.

    Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.

    Time frame: over 52 weeks

  9. Percentage of responders achieving MCID in SGRQ total score in former smokers.

    Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in former smokers.

    Time frame: Week 52

  10. Percentage of responders achieving MCID in SGRQ total score in the overall population of current and former smokers.

    Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in the overall population of current and former smokers.

    Time frame: Week 52

  11. Mean change from baseline in SGRQ total score from in former smokers.

    Difference in mean change from baseline in SGRQ total score in former smokers.

    Time frame: over 52 weeks

  12. Mean change from baseline in SGRQ total score from in the overall population of current and former smokers

    Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.

    Time frame: over 52 weeks

  13. Time to first severe COPD exacerbation in former smokers.

    To evaluate hazard ratio of first severe COPD exacerbation in former smokers.

    Time frame: over 52 weeks

  14. Annualized rate of severe COPD exacerbations in former smokers.

    The rate ratio of severe COPD exacerbations will be assessed in former smokers.

    Time frame: over 52 weeks

  15. Change from baseline in CAT total score.

    Analyses of change from baseline in CAT total score in former smokers.

    Time frame: Week 52

  16. Percentage of participants with a decrease in CAT total score in former smokers.

    Proportion of participants achieving MCID in CAT total score, a decrease in CAT total score of ≥ 2 points from baseline in former smokers.

    Time frame: Week 52

  17. Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.

    Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.

    Time frame: over 52 weeks

  18. Annualized rate of healthcare resource utilization in former smokers.

    Annualized rate of healthcare resource utilization in former smokers.

    Time frame: over 52 weeks

  19. The change from baseline in mean number of puffs per day in rescue use in former smokers.

    Difference in mean number of puffs per day from baseline.

    Time frame: over 52 weeks

  20. Trough serum concentrations of tozorakimab.

    Pharmacokinetics: concentrations of tozorakimab in trough serum.

    Time frame: over 52 weeks

  21. Presence of anti-drug antibodies.

    Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.

    Time frame: over 60 weeks

07

Study locations

212 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Montgomery, Alabama 36106, United States
  • Research Site
    Phoenix, Arizona 85044, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Sacramento, California 95821, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Evergreen Park, Illinois 60805, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Kansas 66104, United States
  • Research Site
    Baton Rouge, Louisiana 70816, United States
  • Research Site
    Zachary, Louisiana 70791, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Brick, New Jersey 08724, United States
  • Research Site
    New York, New York 10037, United States
  • Research Site
    The Bronx, New York 10455, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Sayre, Pennsylvania 18840, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Franklin, Tennessee 37067, United States
  • Research Site
    Houston, Texas 77022, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    Salt Lake City, Utah 84108, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Buenos Aires, C1121 ABE, Argentina
  • Research Site
    CABA, C1425BEN, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1414AIF, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mar del Plata, B7600GWV, Argentina
  • Research Site
    Mendoza, M5500CCG, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5101, Belgium
  • Research Site
    Dupnitsa, 2600, Bulgaria
  • Research Site
    Haskovo, 6305, Bulgaria
  • Research Site
    Kozloduy, 3320, Bulgaria
  • Research Site
    Lovech, 5500, Bulgaria
  • Research Site
    Petrich, 2850, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Rousse, 7002, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Sofia, 1000, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Troyan Municipality, 5600, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Calgary, Alberta T3E 7M8, Canada
  • Research Site
    Edmonton, Alberta T5A 4L8, Canada
  • Research Site
    Sherwood Park, Alberta T8L 0N2, Canada
  • Research Site
    Kamloops, British Columbia V2C 5T1, Canada
  • Research Site
    Kelowna, British Columbia V1Y 4N7, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Guelph, Ontario N1H 6J2, Canada
  • Research Site
    Markham, Ontario L3T 0C8, Canada
  • Research Site
    Stouffville, Ontario L4A 1H2, Canada
  • Research Site
    Winchester, Ontario K0C 2K0, Canada
  • Research Site
    Montreal, PQ H3T 1E2, Canada
  • Research Site
    Québec, Quebec G1G 5X1, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Terrebonne, Quebec J6V 2H2, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Broumov, 55001, Czechia
  • Research Site
    Jindřichův Hradec, 377 01, Czechia
  • Research Site
    Liberec, 460 63, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Rokycany, 337 22, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    Næstved, 4700, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Hämeenlinna, 13530, Finland
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Tampere, 33520, Finland
  • Research Site
    Turku, 20100, Finland
  • Research Site
    Turku, FI-20521, Finland
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Edelény, 3780, Hungary
  • Research Site
    Encs, 3860, Hungary

Showing the first 100 of 212 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Watz H, Sciurba FC, Bonini M, Yanez A, Bourdin A, Zheng J, De Soyza A, Janssens W, van den Berge M, Xu JF, Saraiva GL, Jenkins M, Jimenez E, Lofdahl M, Li J, Mikosz M, Kishishita N, Jackson S, Johnson S, Patel R, Fageras M, Psallidas I. Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations. BMJ Open Respir Res. 2026 Jul 20;13(1):e004145. doi: 10.1136/bmjresp-2026-004145. PubMed 42476723 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2026, 48 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 48 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Dec 22, 2021
StartActual
Jan 3, 2022
Primary completionActual
Jan 19, 2026
CompletionActual
Mar 11, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05166889
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 22, 2021
Start date
Jan 3, 2022
Primary completion
Jan 19, 2026
Completion
Mar 11, 2026
Last update
Apr 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion